Cargando…
Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study
The naturally occurring antagonist of interleukin-1, IL-1RA, is highly neuroprotective experimentally, shows few adverse effects, and inhibits the systemic acute phase response to stroke. A single regime pilot study showed slow penetration into cerebrospinal fluid (CSF) at experimentally therapeutic...
Autores principales: | Galea, James, Ogungbenro, Kayode, Hulme, Sharon, Greenhalgh, Andrew, Aarons, Leon, Scarth, Sylvia, Hutchinson, Peter, Grainger, Samantha, King, Andrew, Hopkins, Stephen J, Rothwell, Nancy, Tyrrell, Pippa |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049499/ https://www.ncbi.nlm.nih.gov/pubmed/20628399 http://dx.doi.org/10.1038/jcbfm.2010.103 |
Ejemplares similares
-
Anakinra in COVID-19: important considerations for clinical trials
por: King, Andrew, et al.
Publicado: (2020) -
The effect of intravenous interleukin-1 receptor antagonist on inflammatory mediators in cerebrospinal fluid after subarachnoid haemorrhage: a phase II randomised controlled trial
por: Singh, Navneet, et al.
Publicado: (2014) -
Cerebrospinal fluid and plasma cytokines after subarachnoid haemorrhage: CSF interleukin-6 may be an early marker of infection
por: Hopkins, Stephen J, et al.
Publicado: (2012) -
The role of cortisol in immunosuppression in subarachnoid haemorrhage
por: Hoadley, Margaret E., et al.
Publicado: (2023) -
Predicting survival of pancreatic cancer patients treated with gemcitabine using longitudinal tumour size data
por: Wendling, Thierry, et al.
Publicado: (2016)